Moderna Claims CureVac Broke No-Sue Pact in COVID Vaccine Patent Fight
BNTX sits 16% above its 52-week low of $79.52 on light trading volume (0.2× avg).
Summary
Moderna has fired back in the CureVac patent lawsuit, arguing CureVac broke a prior agreement not to sue over certain COVID vaccine patents. The alleged pact was made in exchange for Moderna waiving a conflict of interest for an expert witness in CureVac's separate case against BioNTech. Moderna also asserts non-infringement and claims the patents are invalid because CureVac withheld information from the USPTO. This escalates the multi-front patent war over mRNA vaccine technology, directly involving BioNTech as CureVac's parent and a co-litigant against Moderna. The outcome could affect royalty obligations and competitive dynamics across the COVID vaccine market.
At the time of this announcement, BNTX was trading at $92.63 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $23.1B. The 52-week trading range was $79.52 to $124.00. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.